Precision Monitoring in Acute Leukemias: Applying MRD Data in Clinical Practice

This session explores the evolving role of measurable residual disease (MRD) in the management of acute leukemias, with emphasis on how MRD data can be integrated into real-world clinical decision-making. Dr. Madhu Ouseph will review advances in MRD detection technologies, including next-generation sequencing and multiparameter flow cytometry, and their prognostic and predictive value across AML and ALL. Key data from recent hematology meetings will highlight MRD-guided risk stratification, the role of MRD in informing transplant decisions, and its emerging use as a surrogate endpoint in clinical trials. The session will also address practical challenges, including assay standardization, timing of assessment, and interpretation of low-level positivity.